Logo

Cell Signaling Technology Renews Research Pact with Ortho Biotech

Nov 11, 2008
NEW YORK (GenomeWeb News) – Cell Signaling Technology has renewed a biomarker research agreement with Ortho Biotech Oncology Research & Development, a unit of Johnson & Johnson Pharmaceutical Research & Development.
 
Danvers, Mass.-based CST said that it would use its PhosphoScan and PTMScan technologies in research aimed at discovering and validating biomarkers for multiple enzyme target classes and lead small-molecule inhibitors for cancer treatment. The technologies are used for profiling and discovery of phosphorylation and other post-translational modifications in cells and tissues.
 
Financial terms and other details of the collaboration were not disclosed.

Breaking News
The Scan

Harvard Team Report One-Time Base Editing Treatment for Motor Neuron Disease in Mice

A base-editing approach restored SMN levels and improved motor function in a mouse model of spinal muscular atrophy, a new Science paper reports.

International Team Examines History of North American Horses

Genetic and other analyses presented in Science find that horses spread to the northern Rockies and Great Plains by the first half of the 17th century.

New Study Examines Genetic Dominance Within UK Biobank

Researchers analyze instances of genetic dominance within UK Biobank data, as they report in Science.

Cell Signaling Pathway Identified as Metastasis Suppressor

A new study in Nature homes in on the STING pathway as a suppressor of metastasis in a mouse model of lung cancer.